CAPSTONE THERAP. DL-,0005 Logo
US14068E2081
A2PRWA
CAPS

CAPSTONE THERAP. DL-,0005

Caricamento quotazioni...

Previsioni

Acquista
  1
Mantieni
  0
Vendi
  0

  • Capstone Energy+ increases production for data centers and expands manufacturing capacity

    Capstone Energy+ reports rising demand from data centers and has expanded manufacturing in Van Nuys from 2 MW to 7 MW per week in single‑shift operation; in two shifts annual capacity could exceed 700 MW. The company highlights its low‑maintenance turbine design, is working on 800‑V‑DC compatibility, lower emissions, a restart of the C250 engine, and a roadmap to 500 kW/1 MW systems. Capstone sees near‑term growth in data centers but also aims to address ports, utilities and substations and is focusing on KWK/KWKK with high heat‑recovery efficiency. After an earlier Chapter‑11 proceeding, management is working with Monarch to clean up the capital structure and expects improvements within about six months. » Altro su de.investing.com


  • Capstone secures $10 million convertible note to finance acquisitions

    Capstone Holding Corp. has secured a $10 million convertible note facility to fund its acquisition strategy and drive growth. The first tranche of $3 million will be used to acquire a distributor in the southeastern United States, while the company reaffirms its financial targets for 2025. CEO Matt Lipman highlights the flexibility of the financing and the goal to increase revenue to $100 million. » Altro su de.investing.com

Nel 1998, CAPSTONE THERAP. DL-,0005 ha già distribuito 0,11 € di dividendi. L'ultimo pagamento è avvenuto a maggio 1998.

Dati finanziari dell'azienda

Nell'ultimo trimestre, CAPSTONE THERAP. DL-,0005 ha registrato ricavi pari a 18,82 Mln € e un utile netto di -1,21 Mln €
(EUR) giugno 2026
YoY
Ricavi 18,82 Mln 72,61%
Utile lordo 5,26 Mln 97,94%
Utile netto -1,21 Mln 103,60%
EBITDA 2,31 Mln 1964,62%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
2,32 Mln €
Numero di azioni
15,2 Mln
Massimo/minimo a 52 settimane
1,31 € - 0,15 €
Dividendi No
Beta
-1,50
Rapporto P/E
-0,05
Rapporto PEG
0,00
Rapporto P/B
0,18
Rapporto P/S
0,04

Profilo aziendale

Capstone Therapeutics Corp. ist ein Biotechnologieunternehmen, das neuartige Peptide und andere Moleküle zur Unterstützung von Patienten mit unterversorgten Krankheiten in den Vereinigten Staaten entwickelt. Es entwickelt das Apo-E-mimetische Peptidmolekül AEM-28 und seine Analoga, die klinische Studien der Phase Ia und der Phase Ib/IIa für den Lipoproteinstoffwechsel abgeschlossen haben. Das Unternehmen war früher als OrthoLogic Corp. bekannt und änderte im Mai 2010 seinen Namen in Capstone Therapeutics Corp. Capstone Therapeutics Corp. wurde 1987 gegründet und hat seinen Hauptsitz in Tempe, Arizona.

Nome
CAPSTONE THERAP. DL-,0005
CEO
Matthew E. Lipman
Sede centrale Alsip, il
Stati Uniti
Sito web
Quotazione in borsa
28/01/1993
Dipendenti 93

Simboli di borsa

Borsa Simbolo
Pnk
CAPS
🍪

Parqet  usa i cookie. Scopri di più